Subtype
Male Reproductive System Neoplasm
CI-CAN-00001107Explore in graph →
Non-malignant1,533 active trials27 approved drugs58 evidence items
- NCIt
- C3054
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001107Explore in graph →
Clinical trials
6,899 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01424930 | A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 25 | Janssen-Ortho Inc., CanadaINDUSTRY | 1 | Jul 25, 2014 | clinicaltrials |
| NCT02054793 | Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC) | withdrawn | Phase 1 / Phase 2 | 0 | Emmanuel Antonarakis, MDOTHER | 1 |
| Jul 23, 2014 |
| clinicaltrials |
| NCT00544440 | An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma | completed | Phase 2 | 57 | Janssen Research & Development, LLCINDUSTRY | 1 | Jul 17, 2014 | clinicaltrials |
| NCT00349557 | Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer | completed | Phase 2 | 18 | Benaroya Research InstituteOTHER | 1 | Jul 16, 2014 | clinicaltrials |
| NCT01678313 | Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels | completed | Phase 2 | 140 | Buddhist Tzu Chi General HospitalOTHER | 1 | Jul 15, 2014 | clinicaltrials |
| NCT00278993 | Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy | completed | Phase 2 | 108 | Eisai Inc.INDUSTRY | 1 | Jul 14, 2014 | clinicaltrials |
| NCT00919035 | Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients | completed | Phase 2 | 21 | Oncology Specialists, S.C.OTHER | 1 | Jun 30, 2014 | clinicaltrials |
| NCT00459654 | A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer | completed | Phase 2 | 64 | BayerINDUSTRY | 2 | Jun 25, 2014 | clinicaltrials |
| NCT00337077 | Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | completed | Phase 2 | 121 | National Cancer Institute (NCI)NIH | 1 | Jun 23, 2014 | clinicaltrials |
| NCT02161692 | Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell Tumors | completed | Phase 2 | — | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jun 12, 2014 | clinicaltrials |
| NCT00515112 | Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer | terminated | Phase 2 | 6 | University of ChicagoOTHER | 1 | Jun 11, 2014 | clinicaltrials |
| NCT00593853 | Efficacy Study of Methylphenidate Hydrochloride to Reduce Fatigue in Prostate Cancer Patients Receiving Hormone Therapy | terminated | Phase 2 | 33 | University Health Network, TorontoOTHER | 1 | Jun 4, 2014 | clinicaltrials |
| NCT00089076 | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma | terminated | Phase 1 / Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00054639 | Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma | completed | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00390468 | Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00330161 | Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer | completed | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | May 26, 2014 | clinicaltrials |
| NCT02145494 | The SPARC Trial: Stereotactic Prostate Ablative Radiotherapy Using Cyberknife(SPARC) | unknown | Phase 2 | 20 | Royal Marsden NHS Foundation TrustOTHER | 1 | May 23, 2014 | clinicaltrials |
| NCT00183924 | Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy. | completed | Phase 2 | 20 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00176605 | Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer | completed | Phase 2 | 15 | Rutgers, The State University of New JerseyOTHER | 1 | May 20, 2014 | clinicaltrials |
| NCT00706498 | Phase II Study of BI 2536 in Prostate Cancer | completed | Phase 2 | 20 | Boehringer IngelheimINDUSTRY | 1 | May 16, 2014 | clinicaltrials |
| NCT01088529 | Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer | completed | Phase 2 | 66 | Cougar Biotechnology, Inc.INDUSTRY | 1 | May 15, 2014 | clinicaltrials |
| NCT00474383 | An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy | completed | Phase 2 | 47 | Cougar Biotechnology, Inc.INDUSTRY | 2 | May 12, 2014 | clinicaltrials |
| NCT00087139 | Ixabepilone in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 124 | National Cancer Institute (NCI)NIH | 1 | May 9, 2014 | clinicaltrials |
| NCT00473746 | Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer | completed | Phase 1 / Phase 2 | 66 | Janssen Research & Development, LLCINDUSTRY | 1 | Apr 29, 2014 | clinicaltrials |
| NCT00425503 | PS-341 Followed by Removal of Prostate for Those With Prostate Cancer | completed | Phase 2 | 40 | Baylor College of MedicineOTHER | 1 | Apr 21, 2014 | clinicaltrials |
| NCT01483586 | Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer | terminated | Phase 2 | 90 | KangLaiTe USAINDUSTRY | 1 | Apr 14, 2014 | clinicaltrials |
| NCT00678015 | Pharmacokinetic and Efficacy Study of Nordihydroguaiaretic Acid (NDGA) in Non Metastatic Recurrent Prostate Cancer | terminated | Phase 2 | 12 | University of California, San FranciscoOTHER | 1 | Apr 9, 2014 | clinicaltrials |
| NCT00072670 | A Phase 2 Study of Trabectedin (Yondelis) in Adult Male Participants With Advanced Prostate Cancer | completed | Phase 2 | 59 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 1 | Apr 8, 2014 | clinicaltrials |
| NCT00414388 | Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer | completed | Phase 1 / Phase 2 | 22 | Oncology Specialists, S.C.OTHER | 1 | Apr 7, 2014 | clinicaltrials |
| NCT00487721 | The Effect of High-dose Silybin-phytosome in Men With Prostate Cancer | completed | Phase 2 | 12 | University of Colorado, DenverOTHER | 1 | Mar 31, 2014 | clinicaltrials |
| NCT00439270 | Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer | completed | Phase 1 / Phase 2 | 49 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 28, 2014 | clinicaltrials |
| NCT00654186 | Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients | completed | Phase 2 | 32 | Oncology Specialists, S.C.OTHER | 1 | Mar 28, 2014 | clinicaltrials |
| NCT00473512 | A Safety and Efficacy Study of Abiraterone Acetate in Participants With Prostate Cancer Who Have Failed Hormone Therapy | completed | Phase 1 / Phase 2 | 54 | Cougar Biotechnology, Inc.INDUSTRY | 1 | Mar 27, 2014 | clinicaltrials |
| NCT00452556 | The ELDORADO (Eligard®, Docetaxel and Radiotherapy) Study | unknown | Phase 2 | 86 | Nova Scotia Cancer CentreOTHER | 1 | Mar 19, 2014 | clinicaltrials |
| NCT00859729 | Dose Finding Study of a DNA Vaccine Delivered With Intradermal Electroporation in Patients With Prostate Cancer | completed | Phase 1 / Phase 2 | 15 | Uppsala UniversityOTHER | 1 | Mar 17, 2014 | clinicaltrials |
| NCT00770848 | AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 162 | AmgenINDUSTRY | 0 | Mar 10, 2014 | clinicaltrials |
| NCT01338792 | Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer | completed | Phase 2 | 47 | University of Southern CaliforniaOTHER | 1 | Mar 10, 2014 | clinicaltrials |
| NCT00015977 | Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | completed | Phase 2 | 13 | University of ChicagoOTHER | 1 | Mar 7, 2014 | clinicaltrials |
| NCT00258284 | Capecitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 30 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 6, 2014 | clinicaltrials |
| NCT00078923 | Soy Isoflavones in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage I or Stage II Adenocarcinoma of the Prostate | completed | Phase 2 | 32 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 5, 2014 | clinicaltrials |
| NCT00887640 | Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer | terminated | Phase 2 | 11 | Duke UniversityOTHER | 1 | Feb 26, 2014 | clinicaltrials |
| NCT01734681 | Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | GenSpera, Inc.INDUSTRY | 1 | Feb 19, 2014 | clinicaltrials |
| NCT01176513 | GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer | terminated | Phase 2 | 25 | GE HealthcareINDUSTRY | 1 | Feb 14, 2014 | clinicaltrials |
| NCT01409473 | Stereotactic Body Radiotherapy (SBRT) With Concurrent Boost for Low- and Intermediate-Risk Prostate Cancer(Prostate SBRT) | withdrawn | Phase 2 | 0 | Rocky Mountain Cancer CentersOTHER | 1 | Feb 12, 2014 | clinicaltrials |
| NCT01715064 | Acute Effects of Exercise on the Cortical Silent Period in Prostate Cancer Patients | completed | Phase 2 / Phase 3 | 36 | University of Guelph-HumberOTHER | 1 | Feb 10, 2014 | clinicaltrials |
| NCT00295802 | Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer | unknown | Phase 2 / Phase 3 | 141 | EDAP TMS S.A.INDUSTRY | 2 | Feb 7, 2014 | clinicaltrials |
| NCT01250717 | Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer | completed | Phase 2 | 28 | Beth Israel Deaconess Medical CenterOTHER | 1 | Feb 4, 2014 | clinicaltrials |
| NCT00003312 | Brachytherapy in Treating Patients With Prostate Cancer | completed | Phase 2 | 95 | Radiation Therapy Oncology GroupNETWORK | 2 | Jan 24, 2014 | clinicaltrials |
| NCT00479635 | A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer | terminated | Phase 2 | 26 | Cortice Biosciences, Inc.INDUSTRY | 1 | Jan 22, 2014 | clinicaltrials |
| NCT02037464 | CAPSAICIN Trial: Assessing Capsaicin as a Chemopreventive Agent for Prostate Cancer(CAPSAICIN) | unknown | Phase 2 | 100 | Sunnybrook Health Sciences CentreOTHER | 1 | Jan 16, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Jul 25, 2014source: clinicaltrials